Pfizer Inc. $PFE Stock Holdings Lifted by Groupe la Francaise

Key Points

• Groupe la Francaise increased its holdings in Pfizer by 13.5%, owning 162,213 shares worth $3.97 million as of the latest SEC filing.
• Pfizer's recent quarterly earnings report showed an EPS of $0.78, outperforming analysts' expectations of $0.58 and marking a 10.3% increase in year-over-year revenue to $14.65 billion.
• The company has announced a quarterly dividend of $0.43 per share, offering an annualized yield of 6.7%, with a payout ratio of 91.49%.

Groupe la Francaise grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 162,213 shares of the biopharmaceutical company's stock after buying an additional 19,291 shares during the quarter. Groupe la Francaise's holdings in Pfizer were worth $3,971,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. AlphaQuest LLC increased its holdings in shares of Pfizer by 38.3% during the 1st quarter. AlphaQuest LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $844,000 after acquiring an additional 9,221 shares during the last quarter. Cutler Capital Management LLC increased its stake in shares of Pfizer by 1.4% in the first quarter. Cutler Capital Management LLC now owns 250,397 shares of the biopharmaceutical company's stock valued at $6,345,000 after buying an additional 3,503 shares during the period. Van Hulzen Asset Management LLC grew its stake in Pfizer by 3.5% during the first quarter. Van Hulzen Asset Management LLC now owns 24,542 shares of the biopharmaceutical company's stock worth $622,000 after purchasing an additional 830 shares during the period. Strategies Wealth Advisors LLC bought a new position in Pfizer in the first quarter worth approximately $261,000. Finally, Allstate Corp boosted its holdings in Pfizer by 32.3% in the first quarter. Allstate Corp now owns 222,263 shares of the biopharmaceutical company's stock worth $5,632,000 after acquiring an additional 54,287 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Redburn Atlantic dropped their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.12.

Pfizer Price Performance

PFE stock traded down $0.73 during mid-day trading on Monday, reaching $25.15. The company's stock had a trading volume of 32,304,503 shares, compared to its average volume of 44,473,524. The company's 50 day moving average is $24.72 and its two-hundred day moving average is $24.39. The stock has a market cap of $142.99 billion, a PE ratio of 13.38, a P/E/G ratio of 0.92 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the company posted $0.60 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer's dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.